Replication-deficient adenovirus induces aost topoisomerase I activity: Implications for adenovirus-mediated gene expression

Gideon Zamir*, Evelyne Zeira, Andrew E. Gelman, Abraham Shaked, Kim M. Olthoff, Ahmed Eid, Eithan Galun

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Replication-deficient adenoviruses are useful vectors for the transfer of therapeutic transgenes to malignant and non-malignant tissues. Yet their clinical application is limited by the potential toxicity of viral infection and the transient nature of transgene expression. Although transgene expression from adenovirus vectors is initially higher than expression of transgenes transduced by other viral or non-viral vectors, it is often insufficient to generate a significant therapeutic effect. We addressed this issue by searching for DNA-targeted viral-induced host responses potentially restricting transgene expression. Nuclear protein extracts from livers of rats systemically infected with replication-deficient adenovirus exhibited enhanced topoisomerase I activity compared with extracts from uninfected animals. Consequently, the inhibition of topoisomerase I by the anti-cancer drug topotecan greatly enhanced transgene expression in adenovirus-infected hepatic cells, colon cancer and prostate cancer cell cultures, mouse liver, human ex vivo tumor specimens, and mouse tumor in vivo. The enhancement could not be ascribed to non-specific genotoxic stress, cell death, or cell-cycle perturbation. These findings are significant for gene therapy as they reveal novel aspects of the host anti-adenovirus response and set the stage for the development of a rational molecular-pharmacological approach to increase the effectiveness, and safety, of adenovirus-mediated cancer therapeutics.

Original languageAmerican English
Pages (from-to)772-781
Number of pages10
JournalMolecular Therapy
Issue number4
StatePublished - Apr 2007
Externally publishedYes

Bibliographical note

Funding Information:
G.Z. is supported by a grant from the Israeli Ministry of Health, A.S. is supported by National Institutes of Health grant RO1 AI144554, and E.G. is supported by grants from the Israeli Ministry of Science through the grant to the National Gene Therapy Knowledge Center, Israeli Science Foundation, and by the European Community grant LSHB-CT-2004-512034. E.G. is also supported by the Blum, Grinspoon, and Horowitz & Wolfson foundations.


Dive into the research topics of 'Replication-deficient adenovirus induces aost topoisomerase I activity: Implications for adenovirus-mediated gene expression'. Together they form a unique fingerprint.

Cite this